Brief: Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 30.1 Mln
26/08/2026 06:34
BRIEF-Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 30.1 Mln Aug 26 (Reuters) - Infant Bacterial Therapeutics AB IBTb.ST:
Q2 NET SALES KSEK 0 (0)
Q2 OPERATING INCOME KSEK -30,109 (-20,126)
Source text: ID:nMFN7q6WR4
Further company coverage: [IBTb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Infant Bacterial Therapeutics AB
See all newsBrief: Infant Bacterial Therapeutics Gets FDA Request For Type B Pre-BLA Meeting
Brief: Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 30.1 Mln
Brief: Infant Bacterial Therapeutics CFO Leaves The Company
Brief: Infant Bacterial Announces Phase III IBP-9414 Study Results
Brief: Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln